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An 8-year experience with type II endoleaks:
Natural history suggests selective intervention is a
safe approach
Daniel Silverberg, MD, Donald T. Baril, MD, Sharif H. Ellozy, MD, Alfio Carroccio, MD,
Savannah E. Greyrose, MS, Robert A. Lookstein, MD, and Michael L. Marin, MD, New York, NY
Objective: The treatment of type II endoleaks remains controversial because little is known about their long-term natural
history and impact on changes in aneurysm morphology. This study reviews type II endoleaks occurring in patients after
endovascular abdominal aortic aneurysm repair (EVAR) at a single-institution over an 8-year period.
Methods: All patients undergoing EVAR who had type II endoleaks documented on follow-up imaging studies at our
institution between January 1997 and March 2005 were reviewed. Data regarding patient demographics in addition to
aneurysm size, device type, operative complications, and secondary interventions were reviewed. Outcomes evaluated
included the rate of spontaneous sealing, freedom from secondary intervention, and aneurysm enlargement, rupture, or
conversion.
Results:Type II endoleaks were present in 154 of 965 patients (16.0%) undergoing EVAR.Mean follow-up time was 22.0
months (range, 1 to 72 months). Fifty-five patients (35.7%) with type II endoleaks sealed spontaneously in a mean time
of 14.5 months. According to Kaplan-Meier analysis, approximately 75% of type II endoleaks sealed spontaneously
within a 5-year period. Nineteen patients (12.3%) with type II endoleaks were treated at a mean time of 19.9 months at
the operating surgeon’s discretion, including 13 with sac enlargement >5 mm. Kaplan-Meier analysis estimated that
approximately 65% of the patients remained free of intervention after a period of 4 years. Thirteen patients (8.4%)
experienced aneurysm sac enlargement>5 mm. Kaplan-Meier analysis estimated that approximately 80% of patients with
type II endoleaks remained free of sac enlargement >5 mm over a 4-year period. No patients with type II endoleaks
experienced rupture or required conversion to open repair during their follow-up. Cox regression analysis showed that
cancer, coronary artery disease, and chronic obstructive pulmonary disease were associated with earlier spontaneous
closure of the type II endoleaks (P < .05).
Conclusions:We observed that type II endoleaks have a relatively benign course, and in the absence of sac expansion, can
be followed for a prolonged course of time without the need for intervention. The rate of spontaneous seal continues to
increase with time and, therefore, close follow-up of patients with type II endoleaks who show no signs of aneurysm
expansion is a safe approach. For patients in whom the exact etiology of their endoleak is in question, dynamic imaging
should be used to exclude the presence of a type I endoleak. (J Vasc Surg 2006;44:453-59.)Endovascular aneurysm repair (EVAR) has offered a
minimally invasive alternative to open abdominal aortic
aneurysm (AAA) repair since its initial description by Parodi
et al in 1991.1 EVAR is based on the same principles as the
traditional open AAA repair, which is complete exclusion of
arterial perfusion from the aneurysm sac with resultant pre-
vention of aneurysm rupture. Mid-term results using this
technique with second-generation and third-generation
devices have been excellent.2 The long-term durability of
EVAR continues to be questioned, however, largely be-
cause of endoleak, which is the persistence of blood flow
outside the graft and within the aneurysm sac.3-5
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doi:10.1016/j.jvs.2006.04.058There is little debate regarding the treatment of type I and
type III endoleaks, which involves stent-graft attachment sites
or junction points between graft components, respectively.
Type I and type III endoleaks signify incomplete exclusion of
the aneurysm sac from systemic arterial pressure and, there-
fore, incomplete aneurysm repair and should be treated
promptly. The treatment of type II endoleaks, which are
related to retrograde flow into the aneurysm sac via patent
collaterals, most commonly lumbar arteries or the inferior
mesenteric artery (IMA), remains controversial.
The long-term natural history of type II endoleaks has
not yet been fully elucidated. Several reports have related
aneurysm rupture to type II endoleaks.6,7 Additional re-
ports have shown that type II endoleaks may produce
systemic arterial pressures within the aneurysm sac, increas-
ing the risk of rupture.8,9 Conversely, other studies have
shown type II endoleaks not to be a risk factor for rupture
after EVAR.10-12 Given this conflicting data, some have
advocated immediate treatment, whereas others limit treat-
ment to only those aneurysms with significant increases in
size.13,14
To gain a better understanding of the natural history of
type II endoleaks, we reviewed our 8-year experience with
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of AAAs to determine the incidence and outcomes of type
II endoleaks.
METHODS
A retrospective review was performed for all patients
undergoing EVAR at our institution between January
1997 and March 2005. Patients gave written informed
consent and were treated in accordance with the approval
of the institutional review board of the Mount Sinai Med-
ical Center. All patients underwent preoperative contrast-
enhanced computed tomography (CT) and arteriography
to evaluate AAA anatomy. Patients were prospectively moni-
tored, and data on demographics, aneurysm size, medical
comorbidities, complications, and secondary interventions
were obtained. Preoperative, perioperative, and postopera-
tive follow-up data were reviewed from these medical
records and archived radiology studies.
Follow-up for all patients undergoing EVAR consisted
of an office visit with the operating surgeon as well as plain
abdominal radiography and three-phase contrast-enhanced
computed tomography angiography (CTA) at 1 month, 6
months, 12 months, and annually thereafter. CTA con-
sisted of a noncontrast study to assess for calcium in the sac
followed by dynamic and late-phase angiographic assess-
ment of the abdominal aorta. Helical images were obtained
from the diaphragm through the femoral heads before, dur-
ing, and after the intravenous bolus administration of non-
ionic contrast material at a rate of 4mL/s for a total volume
of 140 mL. Magnetic resonance angiography (MRA) or
duplex ultrasonography was substituted for CTA in pa-
tients with renal insufficiency. Patients who demonstrated
endoleaks underwent more frequent surveillance imaging
and follow-up.
Patients who were selected for treatment of their en-
doleak underwent transfemoral arteriography with selective
injection of the hypogastric arteries and superiormesenteric
artery to evaluate lumbar and inferior mesenteric artery
components of their endoleak before embolization and to
exclude the presence of type I or type III endoleaks. Inci-
dence of endoleak type II was calculated for the entire
cohort of patients. The study population consisted of all
patients with a type II endoleak. Patients who underwent
preoperative interventions (IMA or internal iliac artery
embolization) and went on to develop a type II endoleak
were included in this study. Preoperative embolization of
the IMA was performed in 12 of the patients with type II
endoleaks, and preoperative embolization of a single inter-
nal iliac artery was performed in 31 patients.
The follow-up period was defined as the time from
endograft implantation to the most recent imaging study.
The time until endoleak seal was calculated from the date of
surgery until the date of imaging when the endoleak was no
longer present. The time until endoleak treatment was
calculated from the date of surgery until the date when the
endoleak was treated.
Statistical analysis was performed using the statistical
software package SPSS 13.0 (SPSS Inc, Chicago, Ill) andGraphPad Prism (GraphPad Software, Inc, San Diego,
Calif). Kaplan-Meier tables were used to estimate the rate
of spontaneous seal, aneurysm sac enlargement, and free-
dom from intervention in patients with type II endoleaks.
When rates of sealing were calculated, patients who were
treated for their type II endoleaks were considered as
“failure to spontaneously seal,” and were censored at the
time of intervention. The incidence of type II endoleak
development related to device type was examined using 2
analysis. The association between different comorbidities
and seal rate was examined using the Student’s t test for
continuous variables and 2 for categoric variables. Multi-
variate analysis was done using Cox regression.
RESULTS
During a period of 8 years, 965 patients underwent
EVAR at our institution. Endovascular stent-grafts used
for the initial AAA repair that developed type II endoleaks
were the Talent (Medtronic World Medical, Sunrise, Fla),
the Excluder (W. L. Gore & Assoc, Flagstaff, Ariz), the
AneuRx (Medtronic/AVE, Santa Rosa, Calif), the Ancure
(Guidant, Menlo Park, Calif), the Fortron (Cordis/John-
son & Johnson, Warren, NJ), the Teramed (Teramed,
Minneapolis, Minn), and the Zenith (Cook, Bloomington,
Ind). Of these, 154 were found to have type II endoleaks
documented at the time of their initial follow-up visit or at
any time thereafter.
The configurations of these grafts were 137 bifurcated,
12 aortouniiliac, and five aortoaortic. The overall type II
endoleak rate during this period was 16.0% (154/965);
however, this rate should be evaluated with the knowledge
that several of our patients were treated preoperatively with
coil embolization of the IMA or internal iliac arteries dur-
ing the period reviewed. Device-specific rates of type II
endoleak development during this time were Talent, 17.6%
(120/683); Excluder, 15.0% (12/80); AneuRx, 9.2% (9/
99); Ancure, 44.4% (4/9); Fortron, 9.3% (4/43); Ter-
amed, 40% (4/10); and Zenith, 14.3% (1/7). Despite the
variance in occurrence rates, the difference between devices
with regard to type II endoleak development (P .52) was
Table I. Characteristics and comorbidities of patients
with type II endoleaks
N %
Gender
Male 133 86.4
Female 21 13.6
Comorbidities
CAD 75 48.7
Hypertension 111 72.0
Hypercholesterolemia 73 47.4
COPD 33 21.4
Diabetes mellitus 18 12.0
Malignancies 27 17.5
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary
disease.not statistically significant. Mean patient age was 76.1 years
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women. Patient demographics and comorbidities are doc-
umented in Table I. Mean initial sac size was 59.8 mm
(range, 31 to 110 mm). The mean follow-up time was 22.0
months (range, 1 to 72 months).
Of the 154 patients reviewed, 55 (35.7%) had type II
endoleaks that sealed spontaneously. The mean time until
spontaneous seal was 14.5 months (range, 0.3 to 36.3
months). During the study period, 19 patients were treated
for type II endoleaks with coil embolization via either
transfemoral or translumbar approaches, in select cases.
Mean time until treatment was 19.9 months (range, 0.2 to
51.6 months). Of the 19 patients (12.3%) who underwent
treatment, 13 had aneurysm sac enlargement5 mm. The
remaining six patients were treated at the discretion of the
operating surgeon, but on review, were all noted to have
aneurysm enlargement although it failed to reach 5 mm in
this subgroup. Three patients required two separate treat-
ments for endoleaks originating from different anatomic
locations. A persistent endoleak after treatment developed
in eight patients. Type II endoleaks developed from the
lumbar arteries in all of the patients in our series who
underwent preoperative IMA coil embolization, but none
has required secondary interventions.The mean change in aneurysm size among all the
patients in the study was 0.09 mm (range, –37 to 48 mm).
The mean change in aneurysm size among patients who
were treated was 6.42 mm (range, –6 to 26 mm) from the
time preoperatively until their last follow-up. Mean change
in aneurysm size among untreated patients was –1.23 mm
(range, –37 to 17 mm). Mean change in aneurysm size
among the subgroup of patients who underwent preoper-
ative IMA embolization was –1.75 mm (range, –19 to
5 mm). As previously noted, 13 patients experienced sac
enlargement 5 mm and all of these patients underwent
treatment for their type II endoleaks. (Fig 1). In four
patients, aneurysm enlargement continued after interven-
tions. No patients with type II endoleaks experienced rup-
ture or required conversion to a traditional open repair
during their follow-up.
The Kaplan-Meier survival curve estimated that ap-
proximately 75% of type II endoleaks sealed spontaneously
5 years when observed without intervention (Fig 2).
Kaplan-Meier analysis estimated that approximately 80% of
patients with type II endoleaks remained free of sac enlarge-
ment greater than 5mm during a 4 year-period (Fig 3)
and that approximately 65% of the patients remained free of
Fig 1. A, Computed tomography angiography (CTA) demon-
strates a type II endoleak originating from the inferior mesenteric
artery. B, Arteriography demonstrating the same type II endoleak.
C, CTA after successful endoleak coil embolization.intervention after a 4-year period (Fig 4).
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morbidities, and spontaneous seal of type II endoleaks is
summarized in Table II. A higher rate of spontaneous
sealing was found in patients with cancer, coronary artery
disease (CAD), and chronic obstructive pulmonary disease
(COPD) (Fig 5).
DISCUSSION
The incidence of type II endoleaks after EVAR has
been reported to be 8% to 45%.14-18 The natural history of
type II endoleaks is of great importance to physicians and
patients both because the presence of a type II endoleak
after EVAR frequently leads to reintervention. Only limited
information about the natural history of type II endoleaks is
available, however, because of the variability of surgeons’
decisions to intervene, patient follow-up, and patient life
expectancies, along with the constantly evolving technol-
ogy of devices used for EVAR and imaging techniques used
for follow-up. Because much of the natural history of type
II endoleaks is not yet known, the exact clinical significance
of these endoleaks is also unknown.
There is general consensus in the literature on the
Fig 2. Kaplan-Meier analysis demonstrates the rate of spontane-
ous closure of type II endoleaks.
Fig 3. Kaplan-Meier analysis demonstrates freedom from aneu-
rysm enlargement.management of type I and type III endoleaks; however,the significance and management of type II endoleaks
remains controversial. Several authors have reported a be-
nign course of these endoleaks.10,11,19 Intrasac pressure has
been shown to decrease over time in the presence of type II
endoleaks, although to a lesser degree than those patients
without endoleaks.20 Conversely, ruptured AAAs with doc-
umented type II endoleaks have been reported.6,7 Further-
more, some studies have shown type II endoleaks to be
associated with aneurysm growth,21,22 but others have
demonstrated no change in aneurysm volume.23
Given these reports and the premise that a persistent
endoleak may cause continuous pressurization of the aneu-
rysm sac and ultimately lead to sac expansion and possible
rupture, some authors have supported a more aggressive
approach to obliterating type II endoleaks.8,24 On the
other hand, a more conservative approach in which type II
endoleaks are observed over time and treated only if sac
expansion occurs has been reported to be safe as well as
cost-effective.13
The natural history and the rate of spontaneous sealing
of type II endoleaks over time have not yet been fully
elucidated. Steinmetz et al13 reported that 35 (38%) of 90
patients with type II endoleaks had endoleaks that persisted
6 months.13 In other words, the endoleaks sealed spon-
taneously within the first 6 months in 62% of their patients
with type II endoleaks. Parent et al25 reported their expe-
rience in patients with type II endoleaks and determined
that in 13 (36%) of 36 patients, the endoleaks underwent
spontaneous sealing by 6.2 months.
Given the conflicting data on the management and
natural history of type II endoleaks, it is unclear what
interventions should be performed in the preoperative
management of patients with AAAs who are found to have
patent IMAs or lumbar vessels. Several authors have noted
that a patent IMA or lumbar artery preoperatively is a risk
factor for developing a type II endoleak after EVAR.23,26
Thus, preoperative embolization of either the IMA or
lumbar arteries has been studied in relation to type II
endoleaks. Our own institution has reviewed its experience
Fig 4. Kaplan-Meier analysis demonstrates freedom from rein-
tervention.with preoperative embolization of the IMAs.27 Thirty pa-
ase.
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tion, and at 6 months, this group had a type II endoleak
rate of 17%. In comparison, 54 patients who had patent
IMAs preoperatively and no embolization demonstrated a
type II endoleak rate of 48% at 6 months. Additional
reports have shown similar decreases in the rate of type II
endoleaks with preoperative embolization.22,28
With still little known about the long-term natural
history of type II endoleaks, these may not be necessary
procedures. At present, our approach has been to preoper-
atively embolize IMAs only in patients with large-caliber
IMAs in whom the IMA is easily cannulated and the
procedure is easily performed. Althoughmany of these may
spontaneously seal, for those that do not, preoperative
treatment avoids the riskier, more technically challenging
procedure of postoperative embolization.
Our institution has adapted a less aggressive approach
to the management of type II endoleaks. Persistent type II
endoleaks are not routinely embolized unless sac expansion
has been documented. This has allowed us to observe the
rate of spontaneous seal over a prolonged period of time. In
our patients with type II endoleaks, the rate of spontaneous
closure continues to climb over the entire period of the
follow-up and has not been associated with an increased
risk of sac expansion or other adverse outcome over the
same time period. Furthermore, there were no docu-
mented ruptures associated with type II endoleaks moni-
tored over this time period. The reintervention rate was
similar to other reports, indicating that this approach did
not result in a greater need for late interventions.
Although our institution has adapted a less aggressive
Table II. Influence of factors on spontaneous seal of type
No seal
Mean age (years) 76.9
Initial sac size (mm) 60.2
Sex: patients, n (%)
Male 86 (86)
Female 13 (14)
Cancer, n (%)
Yes 13 (14)
No 86 (86)
CAD, n (%)
Yes 43 (43)
No 56 (57)
COPD, n (%)
Yes 15 (15)
No 84 (85)
Diabetes mellitus, n (%)
Yes 13 (14)
No 86 (86)
Hypercholesterolemia, n (%)
Yes 42 (42)
No 57 (58)
Hypertension, n (%)
Yes 75 (75)
No 24 (25)
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary diseapproach to interventions, we have been liberal with ouruse of dynamic studies to rule out the possibility of a type I
or even a type III endoleak. It is not unusual for patients to
initially be diagnosed with a type II endoleak on CTA but
ultimately determined to have a type I or type III endoleak
as determined by arteriography or cine MRA. These mo-
dalities are invaluable to definitively locate the source of the
endoleak.
Endoleaks have a dynamic natural history andmay have
changing branch vessel involvement and flow patterns.25
We noted several patients in our review who were initially
thought to have type II endoleaks but were found to have
type I endoleaks by dynamic studies. It is difficult to know
whether these patients had type I endoleaks over the course
of their follow-up that were misinterpreted as type II en-
doleaks on their studies or whether there was some degen-
eration to a type I endoleak. Regardless of the mechanism,
patients should be evaluated promptly with further imaging
whenever there is a question of a type I endoleak.
We found an association between cancer, CAD,
COPD, and spontaneous closure of endoleaks. The associ-
ation with COPD and spontaneous closure of type II
endoleaks has been documented previously.14 Why COPD
would increase seal rate is unclear. We found no significant
difference in hematocrit levels between COPD and non-
COPD patients, but it is possible that blood viscosity is
higher in smokers, thus contributing to earlier thrombosis
of the collateral flow into the sac. In addition, the higher
rate of spontaneous closure of type II endoleaks in the
presence of malignancy might be explained by the pro-
thrombotic tendencies of patients with malignancies. Al-
though there is no means of proving this, it has been shown
doleaks
eal Univariate P Multivariate P
4.9 .14 N/A
9.2 .62 N/A
.81 N/A
(83)
(17)
.05 .004
(25)
(75)
.08 .013
(58)
(42)
.01 0
(32)
(68)
.81 .46
(9)
(91)
.1 .152
(56)
(44)
.17 .922
(65)
(35)II en
S
7
5
47
8
14
41
32
23
18
37
5
50
31
24
36
19that, conversely, type II endoleaks may be less likely to
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therapy.29
Our study is limited in part by its retrospective nature.
We determined the time of endoleak seal based on the first
follow-up study in which the leak was absent. It is quite
reasonable to assume the endoleak had sealed at any point
in time before that study. In addition, a few patients with
type II endoleaks without evidence of aneurysm enlarge-
ment were treated early in their course at the operating
surgeon’s preference. Furthermore, preoperative inferior
mesenteric artery embolization was performed more fre-
quently later in the time period of this study. It should also
be noted that almost all of our patients had a Talent device
placed. It appears, however, from our own data and that of
the largest series examining the role of endograft type on
the development of type II endoleaks30 that the incidence
does not appear to be related to device type. Despite these
limitations, this study represents one of the largest series of
patients with type II endoleaks who have been observed
over a significant period of time.
CONCLUSION
We have observed that type II endoleaks have a rela-
tively benign course and, in the absence of sac expansion,
can be monitored for a prolonged course of time without
the need for intervention. We recommend that close
follow-up of patients with type II endoleaks who show no
signs of aneurysm expansion is a safe approach, thus sparing
the patients from unnecessary secondary procedures and
the inherent risk of complications from these interventions.
However, for patients in whom there is a question of the
exact etiology of their endoleak, dynamic imaging in the
form of arteriography or cine MRA should be used to
exclude the presence of a type I endoleak.
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Endoleak, the Achilles heel of endovascular aortic aneurysm repair
(EVAR), is correlatedwith aneurysm sac expansion, the need for conver-
sion, aneurysm rupture, and death. The presence of endoleak is the
most common reason for readmission to the hospital after EVAR and
increases the secondary procedure rate, cost, and length of stay.
Collateral vessel endoleaks (type II), the most prevalent form
of endoleaks, do not behave as a uniform class even though they
share a common etiology—back bleeding from an aortic branch.
As Silverberg et al and others have demonstrated, some of these
leaks will spontaneously thrombose, and some will persist. Some
will transmit systemic pressure to the aneurysm sac and to lead to
rupture of the aneurysm, whereas in other cases, the aneurysm sac
regresses and the patients seem to be protected from aneurysm
rupture despite the presence of an endoleak. Unlike type I and type
III endoleaks, which mandate repair upon their discovery, there is
no clear consensus on how type II endoleaks should best be
treated, or even monitored.
Why are type II endoleaks so different and unpredictable in
their behavior? Vascular surgeons readily understand that type II
endoleaks could not remain patent if only supplied by a single
vessel, because end arteries with no outflow rapidly thrombose.
This explains why most type II endoleaks that are detected imme-
diately postoperatively have disappeared by the time of the first
postoperative computed tomography (CT) scan. For a branch
vessel endoleak to remain patent, it must have both inflow and
outflow. Duplex Doppler ultrasound criteria, which have been
found to be predictive of type II endoleak thrombosis, include a
high-resistance type of flow, whereas what is most predictive of
continuation of the endoleak is a low-resistance, continuous type
flow, indicative of a patent outflow tract. The flow patterns in these
endoleaks are variable, changing with blood pressure, position,
respiration, and other dynamic factors.
This changing flow pattern presents a great challenge to
current imaging modalities and explains the frequent observation
of “intermittent appearance” of a type II endoleak. CT angiogra-
phy (CTA) has been shown repeatedly to lack specificity for
determination of leak type and vessel origin of type II leaksthe sac in patients who have been found to have a type II endoleak
often reveals multiple pairs of lumbar arteries in communication
with each other as well as with other branch vessels, when only a
single vessel was suspected by the screening CTA images.
The emerging understanding of these endoleaks is a picture
analogous to our view of arteriovenous malformations. They are
associated with multiple vessels, which may serve as inflow or
outflow, depending on the prevailing physiologic state at the
moment. The involved vessels share a nidus of communication that
maintains the patency of the type II endoleak.
Treatment of type II endoleaks should focus on disruption of
this nidus, resulting in end arteries without the possibility of
outflow, leading to thrombosis. For this reason, it is no wonder
that type II endoleaks related to patent lumbar arteries developed
in all 12 (100%) of the patients Silverberg et al treated by means of
preoperative inferior mesenteric artery (IMA) embolization! Their
prophylactic strategy addressed individual feeding arteries rather
than the root cause of the endoleak, which is the communication
between multiple arteries. If a prophylactic approach to type II
endoleak is to be developed, the greatest likelihood for success
would likely be to focus on obliteration of the sac and the paths
between branch vessels.
Silverbergetalhavetakenamostly selectiveapproachto intervention
for type II endoleaks, with the notable exception of the previously
mentioned preoperative IMA embolizations, generally reserving inter-
vention for patients who demonstrate significant sac expansion. They
have shown that in the short term (22 months’ mean follow-up), this
approachhasnot resulted inanyaneurysmruptures.Because theydidnot
apply any standard protocol to the treatment of type II endoleak, and in
the absence of a control group for comparison, it is difficult to determine
if the behavior of their endoleak patients is different from that of EVAR
patients in general or even from the natural history of untreated
aneurysms over a 22-month mean follow-up interval. No clear treat-
ment recommendations emerge.
What is clear is that our understanding of type II endoleak and its
treatment is evolving. Patients remain at risk for development of en-
doleaks at all times after EVAR. This is an absolute mandate for contin-
ued, careful surveillance of patients who have undergone EVAR.
